



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_521_24

You asked:

I am researching the usage of high-cost drugs in ophthalmology. Your answers to the following question will be highly appreciated.

For the 4 months from May to August 2024, how many **unique** patients received the following intra-vitreal treatments for any eye condition:

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab - Lucentis

Ranibizumab – Ongavia

Ranibizumab – Ximluci

Our response:

In response to your recent enquiry above please find below a table populated with data that is available to Medicines Management for the period of May 2024 to August 2024 as requested.

With regards to Dexamethasone due to the way the data is recorded in the Medicines Management systems we are only able to provide number of issues as we are not able to identify individual patients.

Medicine	Number of Patients	Number of Issues
Aflibercept	740	
Bevacizumab	9	
Brolucizumab	0	
Dexamethasone	0	63
Faricimab	380	
Ranibizumab - Lucentis	**	
Ranibizumab – Ongavia	0	
Ranibizumab – Ximluci	0	

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low, we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.